Hypnotic drug risks of mortality, infection, depression, and cancer: but lack of benefit [version 3; referees: 2 approved]
This is a review of hypnotic drug risks and benefits. Almost every month, new information appears about the risks of hypnotics (sleeping pills). The most important risks of hypnotics include excess mortality (especially overdose deaths, quiet deaths at night, and suicides), infections, cancer, depre...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
F1000 Research Ltd
2018-11-01
|
| Series: | F1000Research |
| Subjects: | |
| Online Access: | https://f1000research.com/articles/5-918/v3 |
| _version_ | 1828395964205891584 |
|---|---|
| author | Daniel F. Kripke |
| author_facet | Daniel F. Kripke |
| author_sort | Daniel F. Kripke |
| collection | DOAJ |
| description | This is a review of hypnotic drug risks and benefits. Almost every month, new information appears about the risks of hypnotics (sleeping pills). The most important risks of hypnotics include excess mortality (especially overdose deaths, quiet deaths at night, and suicides), infections, cancer, depression, automobile crashes, falls, other accidents, and hypnotic-withdrawal insomnia. Short-term use of one-two prescriptions is associated with even greater risk per dose than long-term use. Hypnotics have usually been prescribed without approved indication, most often with specific contraindications, but even when indicated, there is little or no benefit. The recommended doses objectively increase sleep little if at all, daytime performance is often made worse (not better) and the lack of general health benefits is commonly misrepresented in advertising. Treatments such as the cognitive behavioral treatment of insomnia and bright light treatment of circadian rhythm disorders offer safer and more effective alternative approaches to insomnia. |
| first_indexed | 2024-12-10T08:20:56Z |
| format | Article |
| id | doaj.art-3b023328991b488b85408fb4a0b59800 |
| institution | Directory Open Access Journal |
| issn | 2046-1402 |
| language | English |
| last_indexed | 2024-12-10T08:20:56Z |
| publishDate | 2018-11-01 |
| publisher | F1000 Research Ltd |
| record_format | Article |
| series | F1000Research |
| spelling | doaj.art-3b023328991b488b85408fb4a0b598002022-12-22T01:56:20ZengF1000 Research LtdF1000Research2046-14022018-11-01510.12688/f1000research.8729.318371Hypnotic drug risks of mortality, infection, depression, and cancer: but lack of benefit [version 3; referees: 2 approved]Daniel F. Kripke0University of California, San Diego, La Jolla, CA, 92037-2226, USAThis is a review of hypnotic drug risks and benefits. Almost every month, new information appears about the risks of hypnotics (sleeping pills). The most important risks of hypnotics include excess mortality (especially overdose deaths, quiet deaths at night, and suicides), infections, cancer, depression, automobile crashes, falls, other accidents, and hypnotic-withdrawal insomnia. Short-term use of one-two prescriptions is associated with even greater risk per dose than long-term use. Hypnotics have usually been prescribed without approved indication, most often with specific contraindications, but even when indicated, there is little or no benefit. The recommended doses objectively increase sleep little if at all, daytime performance is often made worse (not better) and the lack of general health benefits is commonly misrepresented in advertising. Treatments such as the cognitive behavioral treatment of insomnia and bright light treatment of circadian rhythm disorders offer safer and more effective alternative approaches to insomnia.https://f1000research.com/articles/5-918/v3Anxiety DisordersMood DisordersNeuropharmacology & PsychopharmacologyNeuropsychiatric Disorders |
| spellingShingle | Daniel F. Kripke Hypnotic drug risks of mortality, infection, depression, and cancer: but lack of benefit [version 3; referees: 2 approved] F1000Research Anxiety Disorders Mood Disorders Neuropharmacology & Psychopharmacology Neuropsychiatric Disorders |
| title | Hypnotic drug risks of mortality, infection, depression, and cancer: but lack of benefit [version 3; referees: 2 approved] |
| title_full | Hypnotic drug risks of mortality, infection, depression, and cancer: but lack of benefit [version 3; referees: 2 approved] |
| title_fullStr | Hypnotic drug risks of mortality, infection, depression, and cancer: but lack of benefit [version 3; referees: 2 approved] |
| title_full_unstemmed | Hypnotic drug risks of mortality, infection, depression, and cancer: but lack of benefit [version 3; referees: 2 approved] |
| title_short | Hypnotic drug risks of mortality, infection, depression, and cancer: but lack of benefit [version 3; referees: 2 approved] |
| title_sort | hypnotic drug risks of mortality infection depression and cancer but lack of benefit version 3 referees 2 approved |
| topic | Anxiety Disorders Mood Disorders Neuropharmacology & Psychopharmacology Neuropsychiatric Disorders |
| url | https://f1000research.com/articles/5-918/v3 |
| work_keys_str_mv | AT danielfkripke hypnoticdrugrisksofmortalityinfectiondepressionandcancerbutlackofbenefitversion3referees2approved |